^
Association details:
| Biomarker: | PIK3CA E545K |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) + Imfinzi (durvalumab) (PD-L1 inhibitor) + Truqap (capivasertib) (AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
515MO - A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)
Published date:
09/13/2021
Excerpt:
We hypothesized that triplet combination of immunotherapy with PARP and PI3K-AKT pathway inhibition is tolerable and may demonstrate activity in pts with relevant pathway defects. We investigated the safety and tolerability, pharmacodynamics (PD) and antitumor activity of Durv+Ola, with escalating doses of Cap. 1 pt with PIK3CA E545K mutant breast Ca had stable disease (SD) for 5 months, and 1 pt with PTEN loss and BRCA1 mutant breast Ca had SD of 6 months despite prior progression on PARP inhibitor. Triplet Cap+Ola+Durv is tolerable with evidence of PD and antitumor activity.
